Healius Limited · ASX:HLS
Healius — H1 2026 Earnings Presentation
19 slides from Healius's earnings presentation, Feb 18, 2026
Slide 1: Half Year Results 1H 2026
Half Year Results 1H 2026 18 February 2026
Slide 2: Important Information: Forward-looking statements
Important Information: Forward-looking statements This presentation may contain forward-looking statements regarding Healius Limited’s financial performance, guidance and business prospects. These statements are subject to risks and uncertainties, many beyond the company’s control and are based on m
Slide 3: Group Overview
Group Overview Paul Anderson Chief Executive Officer & Managing Director 3 Healius 1H26 Results Presentation
Slide 4: Group Results
Group Results Revenue growth on improved volume mix and cost out benefits being realised Revenue Pathology Revenue Financial Performance $688.1m $666.3m Revenue • Group revenue growth of $25.5m (3.8%) to $688.1m. $662.6m in pcp (up 3.8%) $643.8m in pcp (up 3.5%) • Pathology revenue growth of $22.5m
Slide 5: Pathology (excluding Agilex Biolabs)
Pathology (excluding Agilex Biolabs) Improvement in revenue growth, revenue mix changing, customer focus progress, labour cost reduction underway Financial • Revenue growth of $22.5m (3.5%) to $666.3m. • Total cost growth reduced to 1.9% - Labour costs are 50.7% of revenue (51.0% in pcp) and reduced
Slide 6: Agilex Biolabs
Agilex Biolabs Strategic capability enhancement and focus on large molecule development contributes positively Financial • Revenue growth of $3.0m (16.0%) to $21.8m. • EBITDA up $1.9m (65.5%) to $4.8m. • EBIT up $1.6m (145.5%) to $2.7m. Operational • Strategic decision to enhance capability and focu
Slide 7: Digital Investment
Digital Investment Digital milestone achieved - positioning the business for growth by leveraging technology Digital Transformation Our multi-year Digital program has come to an end and from 2H26 onwards, any future investment in Digital will be treated as business as usual and no Program longer a n
Slide 8: T27 Scorecard – Performance Update 1H26
T27 Scorecard – Performance Update 1H26 ✓ Delivery complete ▸ Partially delivered > On track Our aim is to deliver high single digit EBIT margins in FY27 ▸• Collections Productivity: 80% of all ACC episodes digitised (since July 2025) ▸• Collections Productivity: Organisational changes complete; lab
Slide 9: Summary Financials
Summary Financials Andrew Thomson Chief Financial Officer 9 Healius 1H26 Results Presentation
Slide 10: Group Results
Group Results Focused on margin expansion through top line revenue growth and cost reduction strategy 1H26 1H25 Top line revenue growth / strategy to reduce costs $m $m Chg % • Group revenue growth of $25.5m (3.8%) to $688.1m driven by volume and fee Revenue (Underlying) 688.1 662.6 3.8% growth in P
Slide 11: Pathology
Pathology Improved revenue source mix contributing to average fee growth 1H26 1H25 Revenue growth 3.5% - benefiting from mix $m $m Chg % • Revenue growth underpinned by improved mix of Specialists, Hospital and B2B revenues Revenue 666.3 643.8 3.5% - Strong growth continues in Genomics (up 21.6% vs
Slide 12: Agilex Biolabs
Agilex Biolabs Strategic pivot to large molecule work contributes to margin expansion 1H26 1H25 Revenue growth contributing to margin $m $m Chg % improvement and expansion Revenue 21.8 18.8 16.0% • EBIT margin of 12.4% reflects the change in mix as business pivoted away from small molecule to large
Slide 13: Capital Management
Capital Management Conservative capital management until earning consistency is achieved Net cash bridge ($m) Capex • Maintenance capex $9.4m (1H25: $6.4m), (22.7) primarily for replacement of aged laboratory equipment and IT hardware. • Growth capex $12.3m (1H25: $4.6m) mainly consists of investmen
Slide 14: 2H26 Outlook
2H26 Outlook Revenue mix and labour productivity remain key focus areas for 2H26 • Expect earnings for FY26 to be in line with current consensus. • On track to deliver on target of $15m - $20m in annual support cost savings. - $7.3m in annualised savings reported in FY25. - $10.7m in annualised savi
Slide 15: Q&A
Q&A
Slide 16: Appendix
Appendix 16 Healius 1H26 Results Presentation
Slide 17: Pathology Strategy
Pathology Strategy Execution of strategy well underway with a defined plan and progress Focused on providing better services for our patients and referrers to improve the volume and quality of the revenue we generate and to become more efficient in our processes Customer Laboratory Emerging Enabled
Slide 18: Underlying to Reported Reconciliation
Underlying to Reported Reconciliation 1H26 1H25 1H26 1H25 $m $m $m $m Underlying EBIT 7.9 (2.7) Underlying EBIT 7.9 (2.7) Termination and other costs (11.6) (2.5) Interest (23.6) (33.6) Digital transformation costs (9.2) (9.2) Notional interest charged to Lumus Imaging - 7.4 Transaction costs - (1.4
Slide 19: Thank you
Thank you